Why Are HTG Molecular Diagnostics Shares Plunging Today
Why Are HTG Molecular Diagnostics Shares Plunging Today
爲甚麼 HTG 分子診斷股價今天暴跌
- HTG Molecular Diagnostics (NASDAQ:HTGM) stock is down on Tuesday after the company announced a Chapter 11 bankruptcy filing.
- According to the filing, HTG Molecular Diagnostics will operate as a "debtor-in-possession" business during the bankruptcy.
- It's also seeking a variety of first-day motions that will allow it to continue normal operations.
- The filing also accelerates the obligations of the company's debts, including a $2.68 million loan held by Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company.
- HTG Molecular Diagnostics notified the termination of Senior Vice President and Chief Commercial Officer Byron Lawson at the start of the month.
- However, the company also signed a deal for his consulting services during a one-month transition period. This has the company agreeing to pay Lawson $23,000.
- In its Q1 earnings release, the company said partnering discussions had been initiated with global biopharmaceutical companies around its portfolio of drug candidate molecules in oncology and neurodegenerative disease indications.
- In addition, HTG has initiated partnering conversations regarding the use of HTG's drug discovery engine within the partners' portfolios of drug assets.
- HTG Molecular reported Q1 sales of $1 million, on a net loss of $5 million.
- Price Action: HTGM shares are down 45.8% at $0.91 on the last check Tuesday.
- HTG 分子診斷 納斯達克股票代碼：HTGM）宣佈第11章破產申請後，週二股價下跌。
- 根據 備案，HTG Molecular Diagnostics將在破產期間作爲 “債務人控股” 企業運營。
- 它還在尋求各種首日動議，以使其能夠繼續正常運營。
- 該文件還加快了公司債務的償還速度，包括硅谷銀行持有的268萬美元貸款，該銀行現隸屬於硅谷銀行 第一公民銀行和信託公司。
- HTG Molecular Diagnostics已於本月初通知高級副總裁兼首席商務官拜倫·勞森被解僱。
- 但是，該公司還簽署了一項爲期一個月的過渡期內的諮詢服務協議。這使該公司同意向勞森支付23,000美元。
- 該公司在第一季度財報中表示，已經開始與全球生物製藥公司就其在腫瘤學和神經退行性疾病適應症中的候選藥物分子組合進行合作討論。
- 此外，HTG已開始就合作伙伴的藥物資產組合中使用HTG的藥物發現引擎展開合作對話。
- HTG Molucal公佈的第一季度銷售額爲100萬美元，淨虧損500萬美元。
- 價格走勢： 在週二的最後一張支票中，HTGM股價下跌了45.8％，至0.91美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。